Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Todd C. Lee MD MPH FIDSA
300 participants
Jan 15, 2026
INTERVENTIONAL
Conditions
Summary
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention. Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119). If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.
Eligibility
Inclusion Criteria1
- Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
Exclusion Criteria6
- Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)
- Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
- Pregnancy
- Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month
- Allergy to clopidogrel
- Concomitant receipt of oral Xa inhibitor
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will change from aspirin to clopidogrel (without loading dose)
Patients will continue their existing aspirin.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06650488